Low-Dose topiramate plus sodium divalproate for positive responders intolerant to full-dose monotherapy

Headache

Volumn 52, Issue 1, 2012, Pages 129-132

  Krymchantowski, Abouch Valenty ^a   Da Cunha Jevoux, Carla ^a  

^a Headache Center of Rio   (Brazil)

Author keywords

combination; migraine; prevention; sodium divalproate; tolerability; topiramate

Indexed keywords

TOPIRAMATE; VALPROATE SEMISODIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOLLOW UP; HAIR LOSS; HUMAN; MALE; MEMORY DISORDER; MIGRAINE; MONOTHERAPY; MORNING DOSAGE; PAIN ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; FRUCTOSE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84856288500     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.02035.x     Document Type: Article

References (17)

1. Lipton RB, Hamelsky SW, Stewart WF,. Epidemiology and impact of migraine. In:, Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's Headache and Other Head Pain. New York: Oxford University Press; 2001: 85-107.
2. Stewart WF, Shechter A, Lipton RB,. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology. 1994; 44 (Suppl. 4): 24-39.
3. Stewart WF, Lipton RB, Simon D,. Work-related disability: Results from the American Migraine Study. Cephalalgia. 1996; 16: 231-238. (Pubitemid 26189248)
4. Lipton RB, Stewart WF,. Prevalence and impact of migraine. Neurol Clin. 1997; 15: 1-13. (Pubitemid 27098696)
5. Stang PE, Von Korff M,. The diagnosis of headache in primary care: Factors in the agreement of clinical and standardized diagnoses. Headache. 1994; 34: 138-142. (Pubitemid 24129303)
6. Cutrer M,. Antiepileptic drugs: How they work in headache. Headache. 2001; 41 (Suppl. 1): S3-S10.
7. Krymchantowski AV, Bryson J, Lipton RB, Bigal ME,. Neuromodulators for the treatment of headache disorders and fibromyalgia. Curr Pain Headache Rep. 2008; 12: 333-337.
8. Krymchantowski AV, Tavares C, Penteado JD, Jde C, Adriano M,. Topiramate in the preventive treatment of migraine: Experience in a tertiary center. Arq Neuropsiquiatr. 2004; 62: 91-95. (Pubitemid 38489822)
9. Silberstein SD,. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Neurology. 2000; 55: 754-763.
10. Cacabelos P, El Berdei Y, Rivas M, Riveira C, Conde A, Pascual J,. Lower versus higher doses of topiramate in migraine prevention. Neurologia. 2009; 24: 808-810.
11. Pascual J, Leira R, Lainez J,. Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia. 2003; 23: 961-962. (Pubitemid 37521948)
12. Pascual J, Rivas M, Leira R,. Testing the combination beta-blocker plus topiramte in refractory migraine. Acta Neurol Scand. 2007; 115: 81-83. (Pubitemid 46018541)
13. Krymchantowski AV,. Acute treatment of migraine: Breaking the paradigm of monotherapy. BMC Neurol. 2004; 4: 4.
14. Loscher W,. Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol. 1999; 58: 31-59. (Pubitemid 29166878)
15. Mathew NT, Saper JR, Silberstein SD, et al,. Migraine prophylaxis with divalproex. Arch Neurol. 1995; 52: 281-286.
16. Curry WJ, Kulling DL,. Newer antiepileptic drugs: Gabapentin, lamotrigine, felbamate, topiramate and fosphenytoin. Am Fam Physician. 1998; 57: 513-520. (Pubitemid 28084051)
17. Jones MW,. Topiramate-Safety and tolerability. Can J Neurol Sci. 1998; 25: 13-15.